Dapagliflozin significantly improves HFpEF symptoms

Treatment with dapagliflozin improves the symptoms of patients with heart failure with preserved ejection fraction (HFpEF), according to new findings presented at the Heart Failure Society of America's Annual Scientific Meeting.

The PRESERVED-HF trial tracked more than 300 HFpEF patients from 26 different clinical trial sites throughout the United States. While 57% of participants were women, more than 30% were Black.

Participants either took 10 mg of dapagliflozin, an SGLT2 inhibitor, or a placebo for 12 weeks. Researchers examined the medication’s impact on each patient’s Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CS) and six-minute walking distance.

Overall, treatment with dapagliflozin was associated with a change in KCCQ-CS of 5.8 points, a different believed to be both clinically meaningful and statistically significant. The medication also helped patients improve their six-minute walking distance, researchers reported.

“To our knowledge, PRESERVED-HF is the first trial to show compelling benefits of SGLT2 inhibitors on both patient-reported symptoms and physical limitations, as well as objectively measured physical function in individuals with HFpEF—outcomes of great importance to both patients and clinicians,” Mikhail Kosiborod, MD, a cardiologist at Saint Luke’s Mid America Heart Institute in Kansas City, Missouri, said in a prepared statement. “It is especially meaningful for this disease condition, as HFpEF has been called the ‘black hole’ of cardiology because until now we have not been able to find efficacious, disease modifying treatments.”

Reviewing his team’s findings, Kosiborod described dapagliflozin as “an important new treatment option for HFpEF.”

“This is great news for patients and clinicians,” he added. “As a cardiologist and researcher, I am excited about the potential impact of PRESERVED-HF data on the management of this patient population.”

Dapagliflozin, known primarily as an effective treatment for Type 2 diabetes, is manufactured by AstraZeneca under the name Farxiga. Read about additional research into its potential as a heart failure treatment here.

Around the web

Although advanced imaging exams have proven benefits in defining disease severity, new data indicate that more sophisticated studies might not impact outcomes as much as previously thought. 

While the ACC/AHA 2021 Chest Pain Assessment Guidelines included cardiac CT angiography as a top level recommendation, gaps in evidence still need to be filled.

There are now more than 520 FDA-cleared AI algorithms and the majority are for radiology and cardiology, raising the question of who is liable if the AI gets something wrong.

Trimed Popup
Trimed Popup